Barron’sClovis Oncology has delivered big results in a much-waited late-stage clinical trial for its ovarian cancer drug. Is a takeover on the horizon? By. Johanna Bennett. June 19, 2017 10:36 a.m. ET. Text Size; Regular; Medium; Large. Talk about good timing.Clovis Oncology’s 45% Pre-Market Surge, Explained ..
AstraZeneca’s Mystic cancer drug trial fails
pharmaphorumAstraZeneca PLC said a combination of two of its new oncology drugs failed to shrink lung cancer tumors in a closely watched clinical trial, casting doubt on a central part of the company’s ambitious growth plans. The trial, dubbed Mystic, centered on AstraZeneca Shares Crash the Most on Record After Key Cancer Drug Fails ..
Clovis Oncology stock surges 50% on positive late-stage cancer trial results
UtahHerald.comClovis Oncology Inc. CLVS, +0.45% shares surged 50% in premarket trade Monday after the company said its late-stage trial for a cancer drug met its primary endpoint and a key secondary endpoint. Clovis said it plans to try for Food and Drug Clovis’s ovarian cancer drug set for label expansion, shares soar ..
“I’m fresh out of you-know-whats to give.” …
“I’m fresh out of you-know-whats to give.”
Clovis’s ovarian cancer drug set for label expansion, shares soar
Investor’s Business Daily… * Co to apply for U.S. drug label expansion within 4 mths * Shares up 48 pct at $88.50 in premarket trade * Rival Tesaro’s shares down 16.8 pct (Adds shares, details on class action lawsuit) By Natalie GroverJune 19 (Reuters) – Positive late-stage Clovis Oncology’s 45% Pre-Market Surge, Explained ..